MX2022011012A - Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas. - Google Patents
Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas.Info
- Publication number
- MX2022011012A MX2022011012A MX2022011012A MX2022011012A MX2022011012A MX 2022011012 A MX2022011012 A MX 2022011012A MX 2022011012 A MX2022011012 A MX 2022011012A MX 2022011012 A MX2022011012 A MX 2022011012A MX 2022011012 A MX2022011012 A MX 2022011012A
- Authority
- MX
- Mexico
- Prior art keywords
- sina
- molecules
- nucleic acid
- short interfering
- interfering nucleic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986150P | 2020-03-06 | 2020-03-06 | |
| US202063109196P | 2020-11-03 | 2020-11-03 | |
| PCT/US2021/021199 WO2021178885A1 (en) | 2020-03-06 | 2021-03-05 | Modified short interfering nucleic acid (sina) molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011012A true MX2022011012A (es) | 2022-10-07 |
Family
ID=75278356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011012A MX2022011012A (es) | 2020-03-06 | 2021-03-05 | Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas. |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20220364096A1 (enExample) |
| EP (1) | EP4121533A1 (enExample) |
| JP (2) | JP2023515664A (enExample) |
| KR (1) | KR20220163960A (enExample) |
| CN (1) | CN115485384A (enExample) |
| AU (1) | AU2021230601A1 (enExample) |
| BR (1) | BR112022017287A2 (enExample) |
| CA (1) | CA3170466A1 (enExample) |
| CL (1) | CL2022002379A1 (enExample) |
| CO (1) | CO2022014258A2 (enExample) |
| GE (2) | GEP20257742B (enExample) |
| IL (1) | IL296045A (enExample) |
| MX (1) | MX2022011012A (enExample) |
| PE (1) | PE20221578A1 (enExample) |
| PH (1) | PH12022552163A1 (enExample) |
| TW (1) | TW202208625A (enExample) |
| WO (1) | WO2021178885A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202002149XA (en) * | 2017-09-14 | 2020-04-29 | Janssen Biopharma Inc | Galnac derivatives |
| JP2023515664A (ja) * | 2020-03-06 | 2023-04-13 | アリゴス セラピューティクス，インコーポレーテッド | 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用 |
| WO2022087011A1 (en) | 2020-10-21 | 2022-04-28 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| WO2022184852A1 (en) * | 2021-03-03 | 2022-09-09 | Silence Therapeutics Gmbh | Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell |
| WO2022266193A1 (en) | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| WO2023122317A2 (en) * | 2021-12-23 | 2023-06-29 | Aligos Therapeutics, Inc. | SHORT INTERFERING NUCLEIC ACID (SINA) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF |
| WO2023224979A1 (en) * | 2022-05-16 | 2023-11-23 | University Of Massachusetts | Optimized sirna scaffolds |
| EP4541804A4 (en) * | 2022-06-14 | 2026-07-01 | Rona Bioscience Ltd | Cyclic phosphonate-modified nucleotide |
| WO2024033374A1 (en) | 2022-08-11 | 2024-02-15 | Syngenta Crop Protection Ag | Novel arylcarboxamide or arylthioamide compounds |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
| JP2026500298A (ja) | 2022-12-15 | 2026-01-06 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺有害生物剤として有用である新規な二環式カルボキサミド化合物 |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| EP4654973A1 (en) * | 2023-01-26 | 2025-12-03 | Aligos Therapeutics, Inc. | Hepatitis b combination therapies |
| CN121152879A (zh) * | 2023-02-14 | 2025-12-16 | 基愈治疗公司 | 经修饰的双链rna药剂 |
| WO2024254091A1 (en) * | 2023-06-05 | 2024-12-12 | Empirico Inc. | Treatment of fgg related diseases and disorders |
| WO2025032129A1 (en) | 2023-08-08 | 2025-02-13 | Syngenta Crop Protection Ag | Novel aminoindane and aminotetraline compounds |
| CN117024485B (zh) * | 2023-08-11 | 2026-02-13 | 江苏申基生物科技有限公司 | 一种2’-OMe腺苷的合成方法 |
| WO2025096970A2 (en) * | 2023-11-03 | 2025-05-08 | Basecure Therapeutics Llc | Modified oligonucleotides and methods of use thereof |
| CN122228245A (zh) | 2023-11-14 | 2026-06-16 | 先正达农作物保护股份公司 | 新颖的羧酰胺化合物 |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| CN117534717A (zh) * | 2024-01-09 | 2024-02-09 | 凯莱英生命科学技术(天津)有限公司 | 5′-(e)-乙烯基磷酸酯的合成方法 |
| PY2501648A (es) | 2024-01-12 | 2025-10-31 | Syngenta Crop Protection Ag | Nuevos compuestos de carboxamida |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025201529A1 (en) * | 2024-03-29 | 2025-10-02 | Ractigen Therapeutics | Compounds for synthesizing modified small activating rna molecules, modified small activating rna molecules and uses thereof |
| US20250368996A1 (en) | 2024-05-14 | 2025-12-04 | Aligos Therapeutics, Inc. | Modified antisense oligonucleotides for treating hepatitis b virus |
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| CN120796266A (zh) * | 2024-07-08 | 2025-10-17 | 北京悦康科创医药科技股份有限公司 | 一种降低hbv基因表达的反义寡核苷酸及其应用 |
| WO2026120028A1 (en) | 2024-12-04 | 2026-06-11 | Syngenta Crop Protection Ag | Novel heteroaryl carboxamide compounds |
| WO2026119962A1 (en) | 2024-12-04 | 2026-06-11 | Syngenta Crop Protection Ag | Novel phenyl carboxamide compounds |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009002944A1 (en) * | 2007-06-22 | 2008-12-31 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
| CN102753187A (zh) * | 2009-06-03 | 2012-10-24 | 戴瑟纳制药公司 | 肽-dicer底物试剂及其特异性抑制基因表达的方法 |
| WO2011139702A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| PT2726613T (pt) * | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| US9796974B2 (en) * | 2011-11-18 | 2017-10-24 | Alnylam Pharmaceuticals, Inc. | Modified RNAi agents |
| EP3109254B1 (en) * | 2014-02-18 | 2018-04-11 | Osaka University | Crosslinked nucleoside and nucleotide |
| CN115957337A (zh) * | 2015-08-07 | 2023-04-14 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| IL308717A (en) * | 2015-12-07 | 2024-01-01 | Genzyme Corp | Methods and compositions for treating a serpinc1-associated disorder |
| EP3387129A1 (en) * | 2015-12-10 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| JOP20170056B1 (ar) | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| WO2018045317A1 (en) | 2016-09-02 | 2018-03-08 | Dicerna Pharmaceuticals, Inc. | 4'-phosphate analogs and oligonucleotides comprising the same |
| US11015198B2 (en) * | 2017-04-05 | 2021-05-25 | Silence Therapeutics Gmbh | Products and compositions |
| US11324820B2 (en) * | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
| HRP20250277T1 (hr) * | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| CN118638787A (zh) * | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| CA3098623A1 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| WO2019217397A2 (en) * | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for improving strand biased |
| US20200147124A1 (en) | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| JP2023515664A (ja) * | 2020-03-06 | 2023-04-13 | アリゴス セラピューティクス，インコーポレーテッド | 修飾された短い干渉核酸（ｓｉＮＡ）分子およびそれらの使用 |
-
2021
- 2021-03-05 JP JP2022552538A patent/JP2023515664A/ja active Pending
- 2021-03-05 GE GEAP202116053A patent/GEP20257742B/en unknown
- 2021-03-05 CN CN202180032666.3A patent/CN115485384A/zh active Pending
- 2021-03-05 WO PCT/US2021/021199 patent/WO2021178885A1/en not_active Ceased
- 2021-03-05 MX MX2022011012A patent/MX2022011012A/es unknown
- 2021-03-05 BR BR112022017287A patent/BR112022017287A2/pt unknown
- 2021-03-05 PH PH1/2022/552163A patent/PH12022552163A1/en unknown
- 2021-03-05 EP EP21715377.4A patent/EP4121533A1/en active Pending
- 2021-03-05 IL IL296045A patent/IL296045A/en unknown
- 2021-03-05 GE GEAP202416053A patent/GEAP202416053A/en unknown
- 2021-03-05 CA CA3170466A patent/CA3170466A1/en active Pending
- 2021-03-05 TW TW110108015A patent/TW202208625A/zh unknown
- 2021-03-05 KR KR1020227034100A patent/KR20220163960A/ko active Pending
- 2021-03-05 PE PE2022001900A patent/PE20221578A1/es unknown
- 2021-03-05 US US17/194,079 patent/US20220364096A1/en active Pending
- 2021-03-05 AU AU2021230601A patent/AU2021230601A1/en active Pending
-
2022
- 2022-02-15 US US17/672,268 patent/US11549110B2/en active Active
- 2022-09-01 CL CL2022002379A patent/CL2022002379A1/es unknown
- 2022-10-05 CO CONC2022/0014258A patent/CO2022014258A2/es unknown
- 2022-11-29 US US18/059,561 patent/US20230332153A1/en active Pending
-
2023
- 2023-07-28 US US18/361,363 patent/US12129469B2/en active Active
-
2026
- 2026-02-27 JP JP2026030569A patent/JP2026102645A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220364096A1 (en) | 2022-11-17 |
| JP2023515664A (ja) | 2023-04-13 |
| US20220177888A1 (en) | 2022-06-09 |
| PE20221578A1 (es) | 2022-10-06 |
| IL296045A (en) | 2022-10-01 |
| JP2026102645A (ja) | 2026-06-23 |
| CO2022014258A2 (es) | 2022-12-30 |
| US20230365970A1 (en) | 2023-11-16 |
| WO2021178885A1 (en) | 2021-09-10 |
| CL2022002379A1 (es) | 2023-07-28 |
| EP4121533A1 (en) | 2023-01-25 |
| US12129469B2 (en) | 2024-10-29 |
| CA3170466A1 (en) | 2021-09-10 |
| PH12022552163A1 (en) | 2024-01-29 |
| CN115485384A (zh) | 2022-12-16 |
| US20230332153A1 (en) | 2023-10-19 |
| KR20220163960A (ko) | 2022-12-12 |
| AU2021230601A2 (en) | 2022-10-20 |
| BR112022017287A2 (pt) | 2022-11-16 |
| GEP20257742B (en) | 2025-03-10 |
| TW202208625A (zh) | 2022-03-01 |
| GEAP202416053A (en) | 2024-10-10 |
| AU2021230601A1 (en) | 2022-10-06 |
| US11549110B2 (en) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552163A1 (en) | Modified short interfering nucleic acid (sina) molecules and uses thereof | |
| MX2024002782A (es) | Moleculas modificadas de acido nucleico de interferencia corto (anic) y usos de las mismas. | |
| WO2007031877A3 (en) | Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification | |
| IL317505A (en) | CRISPR-directed delivery platforms | |
| MY153691A (en) | Hydroxymethyl substituted rna oligonucleotides and rna complexes | |
| BR0014182A (pt) | Processos e composições para amplificação isotérmica linear de sequências polinucleotìdicas | |
| WO2005044981A3 (en) | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) | |
| AR069821A1 (es) | Composiciones y metodos de uso de la interferencia de arn para el control de nematodos | |
| WO2023201281A3 (en) | Oligonucleotides for atn1 modulation | |
| WO2004007718A3 (en) | Rna-interference by single-stranded rna molecules | |
| WO2006002038A3 (en) | Immunostimulatory oligonucleotide multimers | |
| WO2022084331A3 (en) | Novel ligands for asialoglycoprotein receptor | |
| WO2003052132A3 (en) | Linear and hairpin oligonucleotide analogues comprising intercalator pseudonucleotides | |
| WO2007135685A3 (en) | Compositions for silencing the expression of gibberellin 2-oxidase and uses thereof | |
| EP4471160A3 (en) | Methods and kits for amplification of double stranded dna | |
| DE60213803D1 (en) | Happier mapping | |
| WO2021032777A8 (en) | Oligonucleotide conjugate compositions and methods of use | |
| WO2004065600A3 (en) | Rna interference by palindromic or modified rna molecules | |
| WO2023178144A3 (en) | Galnac compositions for improving sirna bioavailability | |
| WO2007058527A3 (en) | Inducible expression systems | |
| MX2024013951A (es) | Composiciones y metodos para inhibir la expresion de mapt | |
| EP4403646A3 (en) | Dna targets as tissue-specific methylation markers | |
| MX2024011671A (es) | Oligonucleotidos modificados | |
| WO2024182446A3 (en) | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof | |
| WO2024097674A3 (en) | Modified short interfering nucleic acid (sina) molecules and uses thereof |